Targeting type 2 inflammation in bullous pemphigoid: dupilumab as a game changer opens new avenues

Journal Article Accepted manuscript Targeting type 2 inflammation in bullous pemphigoid (BP): dupilumab as game changer opens new avenues Get access Luca Borradori, Luca Borradori Department of Dermatology, University Hospital of Bern, University of Bern, Switzerland Correspondence: Luca Borradori1Email:[email protected] Search for other works by this author on: Oxford Academic Google Scholar Michael Hertl Michael Hertl Department of Dermatology and Allergology, Philipps University, Marburg, Germany Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljae465, https://doi.org/10.1093/bjd/ljae465 Published: 06 December 2024 Article history Received: 18 November 2024 Accepted: 05 December 2024 Published: 06 December 2024